MetaCap

Azora Therapeutics (AZR) vs Xilio Therapeutics (XLO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Azora Therapeutics is the larger company by market cap ($55.0 million vs $53.4 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AZR-24.51%XLO-5.62%
+15%-9%-33%
Oct 28, 20261 yearNov 20, 2026
AZR+1.05%XLO-5.85%
+8%+1%-7%
Oct 26, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AZR versus XLO key metrics
MetricAZRXLO
Share price$3.85$7.56
Market cap$55.00M$53.40M
1-day change-0.52%-1.11%
YTD return—-15.63%
1-year return—-28.29%
5-year return—-97.29%
P/E ratio (TTM)—11.63
EPS (TTM)$-18.09$0.65
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$43.77M
Revenue growth (YoY)—+589.88%
Net income (latest FY)$-7.98M$-35.04M
Operating margin—-95.92%
Net margin—-80.05%
52-week high$8.25$10.71
52-week low$1.31$6.47
Distance from 52-week high-53.33%-29.41%
Analyst consensus—none
Avg. price target upside—+164.55%
Average volume50.12K11.54K
Shares outstanding14.29M7.06M
Employees—76
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Xilio Therapeutics

XLO stock →

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody.

Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees

AZR vs XLO FAQ

Which is bigger, Azora Therapeutics or Xilio Therapeutics?

Azora Therapeutics (AZR) is larger, with a market capitalization of $55.00M compared with $53.40M for Xilio Therapeutics (XLO).

Are Azora Therapeutics and Xilio Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons